A Phase 1 Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Switching to Cabotegravir Ultra Long-acting from Cabotegravir Long-acting in Healthy Adult Volunteers
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 30 Jan 2025 New trial record